Organogenesis Holdings (ORGO) Liabilities and Shareholders Equity (2015 - 2026)

Organogenesis Holdings' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $520.0 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 11.25% year-over-year to $520.0 million in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 12.67% increase from a year earlier, with the FY2025 full-year figure at $598.7 million, up 20.25% from the prior year.
• Liabilities and Shareholders Equity declined to $520.0 million in Q1 2026 per ORGO's latest filing, from $598.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $598.7 million in Q4 2025 and bottomed at $436.3 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $458.5 million (2024), against an average of $471.8 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 36.68% in 2022 and retreated 3.53% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $449.4 million in 2022, then increased by 2.37% to $460.0 million in 2023, then grew by 8.23% to $497.9 million in 2024, then advanced by 20.25% to $598.7 million in 2025, then retreated by 13.15% to $520.0 million in 2026.
• Per Business Quant, the three latest ORGO Liabilities and Shareholders Equity figures stand at $520.0 million (Q1 2026), $598.7 million (Q4 2025), and $509.8 million (Q3 2025).